Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a smartphone app spot early signs of Alzheimer's?

NCT ID NCT07174869

Knowledge-focused Sponsor: Indivi AG Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 12, 2026 · Updated 3 times

Summary

This observational study tests a mobile app that uses a dynamic difficulty adjustment system to personalize cognitive activities for people with mild cognitive impairment or mild Alzheimer's disease, as well as healthy older adults. The goal is to see if the app can reach a stable difficulty level and whether that level differs between the two groups. Fifty-five participants will use the app for six weeks, and researchers will evaluate its ability to distinguish between those with and without cognitive decline.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple app-based tool for early detection or monitoring of cognitive decline.
What could go wrong
This is a small pilot study (55 people) focused on usability and feasibility, not on treatment or diagnosis. The app may not reliably distinguish between groups in larger, more diverse populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

32 people

The number who actually took part.

Started

Sep 2025

Finished

Jul 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Boston University Alzheimer's Disease Research Center (BU ADRC)

Ages

50 to 90 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant is part of BU-ADRC cohort. * Participant is diagnosed with MCI, mild AD, or is classified as HC per BU-ADRC, with available required data for inclusion obtained less than 2 years before the inclusion. * Participant is between 50 and 90 years old, included. * Participant is able to use a smartphone. * Participant has sufficient knowledge of the English language. * Participant is able to and has an intention to follow the study procedures. * Informed Consent as documented by signature. Exclusion Criteria: * Participant has any neurological condition that may be contributing to cognitive impairment (above and beyond that caused by the subject's MCI or AD). * Participant has psychiatric diagnosis or symptoms, (e.g., hallucinations, major depression, or delusions) that could interfere with study procedures. * Participant has a history of stroke or seizures within the last 24 months. * Participant has a Geriatric Depression Scale (GDS) score ≥8. * Participant has a severe visual or hearing impairment that would interfere with capacity to perform cognitive assessments. * Known or suspected non-compliance.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mild Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mild Alzheimer disease Mild cognitive impairment (MCI)

Contacts and locations

Locations

  • Boston University School of Medicine

    Boston, Massachusetts, 02118, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.